000			03833nam a2200409 i 4500
999			_c394076 _d394076
001			394076
003			ES-MaUEC
005			20230102123051.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			220928s2022 si a o |||| 0|eng d
020			_a9789811678974
024	7		_a10.1007/978-981-16-7897-4 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRS431.P75 _b2022 EB
245	0	0	_aTherapeutic Proteins Against Human Diseases _cedited by Fahmida Khatoon Zahid Balouch
250			_a1st edition 2022
264		1	_aSingapore _bSpringer International Publishing _c2022
300			_a1 recurso en línea (IX, 173 páginas) _b1 ilustraciones
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
505	0		_aProteins drug targeting and its therapeutics -- Interferons -- Epidermal growth factor (egf) in wound repair -- Therapeutic protein against autoimmune disorders: Intracellular and extracellular properties -- Prions as Therapeutic proteins and their Prospect as Drug Delivery Agent -- INTERLEUKIN - 2 -- Bioinformatics resources, tools, and strategies in designing therapeutic proteins -- Therapeutic proteins used in human pancreatic disease -- Therapeutic role of soybean-derived lunasin peptide in colon cancer treatment: A recent updates from literature -- Therapeutic peptides in skin and hair disorders. .
520			_aThis book compiles updated research about the implications of therapeutic proteins in various human diseases. The initial chapters of the book provide basic information on the therapeutic proteins and discuss techniques for their formulation, production, and analytic approaches for their characterization. The subsequent chapters shed light on therapies based on therapeutic proteins against metabolic disorders, neurological disorders, cancer, autoimmune disorders, and infectious diseases. Importantly, it presents the factors influencing the immunogenicity of therapeutic proteins, including, genetic factors, disease type, and origin of therapeutic protein, dose frequency, administration route, and treatment duration. The book also reviews the strategies for reducing immunogenicity associated with therapeutic proteins, including PEGylation, site specific mutagenesis, exon shuffling, and humanizing of monoclonal antibodies. Further, it presents strategies for improving the typical drawback associated with protein therapeutics including instability and limited penetration through biological barriers. This book covers various computational methods that are commonly used for designing therapeutic proteins and in silico method for predicting and improving in vivo efficacy of the therapeutic molecules. Lastly, the book highlights the recent advances in developing nanosized delivery systems to improve safety and efficacy of protein therapeutics. This book caters to students and researchers of medicinal chemistry, pharmaceutical sciences and therapeutics. It is also useful to clinicians working with therapeutic proteins.
988			_aSpringer_Medicine_2022
650		7	_2embne _9139861 _aProteínas _xUso terapéutico
700	1		_aZahid Balouch, Fahmida Khatoon _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9789811678967
776	0	8	_iPrinted edition: _z9789811678981
776	0	8	_iPrinted edition: _z9789811678998
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-16-7897-4 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b12/2022 _dz _eb _zSI